June 29, 2017 / 8:36 PM / in 4 months

Cara reports mixed results from pain drug trial, shares plunge

June 29 (Reuters) - Cara Therapeutics Inc on Thursday reported mixed results from a pivotal trial testing the drug developer’s chronic pain treatment in patients with osteoarthritis of the knee or hip.

Shares of the company fell 21.6 percent to $20 after the bell.

The drug developer was testing three dosages of the drug, CR845, against a placebo.

Two dosages of the drug - 1 mg and 2.5 mg - failed to meet the main goal of reducing pain intensity in patients, while the 5 mg dose exhibited a statistically significant reduction in joint pain, the company said. (Reporting by Divya Grover in Bengaluru; Editing by Shounak Dasgupta)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below